PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Antineoplastic Agents
  • Hodgkin Disease
  • Immunotherapy
  • Programmed Cell Death 1 Receptor

abstract

  • Nivolumab had substantial therapeutic activity and an acceptable safety profile in patients with previously heavily treated relapsed or refractory Hodgkin's lymphoma. (Funded by Bristol-Myers Squibb and others; ClinicalTrials.gov number, NCT01592370.).

publication date

  • January 22, 2015

Research

keywords

  • Academic Article

Identity

Language

  • eng

PubMed Central ID

  • PMC4348009

Digital Object Identifier (DOI)

  • 10.1056/NEJMoa1411087

PubMed ID

  • 25482239

Additional Document Info

start page

  • 311

end page

  • 9

volume

  • 372

number

  • 4